Ventilator Weaning Outcome Between NIV-NAVA and Nasal CPAP (or IMV ) Modes in Premature Neonates

NCT ID: NCT04118400

Last Updated: 2020-03-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-10-31

Study Completion Date

2021-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Premature neonates are prone to respiratory distress and need ventilator support because of the rapid breathing and large variations in respiratory patterns. The setting and adjustment of the ventilator for premature neonate is not easy, often resulting in poor patient-ventilator interaction, increased work of breathing, patient discomfort and delayed weaning . Recently, a new ventilation mode (NAVA; Neurally Adjusted Ventilatory Assist) mode, allows the respirator to provide a proportional ventilation mode based on the patients' diaphragm electrical activity, which was validated in many domestic and international clinical researches. The NAVA mode improves patient-ventilator interaction, reduces work of breathing and contributes to early weaning and extubation . When participating in this study, the neonate with receive a special oral tube placement, which is used to replace the original gastric tube to monitor the electrical activity of the diaphragm.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Premature neonates are prone to respiratory distress and need ventilator support because of the rapid breathing and large variations in respiratory patterns. The setting and adjustment of the ventilator for premature neonate is not easy, often resulting in poor patient-ventilator interaction, increased work of breathing, patient discomfort and delayed weaning . Recently, a new ventilation mode (NAVA; Neurally Adjusted Ventilatory Assist) mode, allows the respirator to provide a proportional ventilation mode based on the patients' diaphragm electrical activity, which was validated in many domestic and international clinical researches. The NAVA mode improves patient-ventilator interaction, reduces work of breathing and contributes to early weaning and extubation . When participating in this study, the neonate with receive a special oral tube placement, which is used to replace the original gastric tube to monitor the electrical activity of the diaphragm. The aims of the study are: 1. To select the appropriate ventilation mode and parameters (for example, switch to NIV-NAVA mode); 2. To monitor intermittent apnea, bradycardia and the frequency of cyanosis, 3. To pay attention to the changes in maximum peak pressure, adjust appropriate pressure support, and avoid lung injury. The predicted outcomes of NAVA mode for premature neonate may include : 1. Measurement of the lower PIP value to maintain proper and synchronized ventilation; 2. Monitoring of the diaphragm activity (Edi) signal to evaluate the work of breathing and estimate the weaning time.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Distress Syndrome in Premature Infant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental: NIN-NAVA

* Premature\>30weeks with respiratory distress
* PI to determine eligibility or exclusion
* Randomize to either NIV-NAVA or Nasal CPAP (NIMV) 1:1 randomization
* PI will not be blinded to the intervention (not feasible)
* Place the catheter to optimize position
* ABG or VBG to be obtained at 2 hrs. post NIV-NAVA
* NIV-NAVA settings will be weaned or increased as the clinical situation demands and outlined in the protocol

NIV-NAVA

Intervention Type PROCEDURE

NAVA mode during Non-invasive ventilation

Active Comparator: Nasal CPAP or NIMV

* Premature\>30weeks with respiratory distress
* PI to determine eligibility or exclusion
* Randomize to either NIV-NAVA or Nasal CPAP (NIMV) 1:1 randomization
* PI will not be blinded to the intervention (not feasible)
* Place the catheter to optimize position
* ABG or VBG to be obtained at 2 hrs. post Nasal CPAP or NIMV
* NCPAP or NIMV settings will be weaned or increased as the clinical situation demands and outlined in the protocol

Nasal CPAP or NIMV mode

Intervention Type PROCEDURE

Nasal CPAP or NIMV mode during Non-invasive ventilation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NIV-NAVA

NAVA mode during Non-invasive ventilation

Intervention Type PROCEDURE

Nasal CPAP or NIMV mode

Nasal CPAP or NIMV mode during Non-invasive ventilation

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Premature \>30week
2. Respiratory distress

Exclusion Criteria

1. Premature \< 30weeks
2. ENT contraindication: fistula
3. Contraindication with orogastric tube or nasogastric
Minimum Eligible Age

30 Weeks

Maximum Eligible Age

37 Weeks

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Taipei Medical University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hsin-yu LI

Role: PRINCIPAL_INVESTIGATOR

Taipei Medical University Hospital, Taiwan, R.O.C

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hsin-yu LI

Taipei, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

N201907028

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.